MicroRNA Therapeutics in Cardiovascular Disease

摘要: MicroRNAs are endogenous single-stranded RNAs of approximately 22 nucleotides in length which decrease the level expression specific proteins. miRNAs involved many pathologic conditions such as cancers and neuropsychiatric metabolic diseases. In cardiovascular diseases, have been shown to be proliferation cardiomyocytes non-myocyte cardiac cells, hypertrophy apoptosis, occurrence atrial ventricular arrhythmias, vascular angiogenesis smooth muscle cell pathologies, atherosclerosis. heart failure, promote or inhibit remodeling well modulate pump function. By considering a few examples illustrating value complexity targeting miRNAs, this chapter will describe key data demonstrating potential either prevent (miR-208) improve function (miR-25) failure. biogenesis passenger strand miRNA, called miRNA*, is usually degraded. The effects miR-21* illustrate situation where miRNA* exhibits biological activity. Finally, miRNA-based therapeutics nearly reaching human trials disease area. However, several questions remain fully investigated progress therapeutic approaches successfully. These include strategies druggability parameters delivery characteristics selected candidates required demonstrate clearly efficacy/safety ratio novel therapies.